CA2396149A1 - Transduction de recombinases pour ciblage genetique inductible - Google Patents

Transduction de recombinases pour ciblage genetique inductible Download PDF

Info

Publication number
CA2396149A1
CA2396149A1 CA002396149A CA2396149A CA2396149A1 CA 2396149 A1 CA2396149 A1 CA 2396149A1 CA 002396149 A CA002396149 A CA 002396149A CA 2396149 A CA2396149 A CA 2396149A CA 2396149 A1 CA2396149 A1 CA 2396149A1
Authority
CA
Canada
Prior art keywords
arg
ala
ser
leu
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002396149A
Other languages
English (en)
Inventor
Frieder Schwenk
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Artemis Pharmaceuticals GmbH
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP00100351A external-priority patent/EP1118668A1/fr
Application filed by Individual filed Critical Individual
Publication of CA2396149A1 publication Critical patent/CA2396149A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
    • C07K14/43577—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from flies
    • C07K14/43581—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from flies from Drosophila
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Insects & Arthropods (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

L'invention concerne l'utilisation d'une protéine de fusion comprenant un domaine d'ADN recombinase spécifique de site et un domaine de transduction de protéines pour la préparation d'un agent afin d'induire une modification du gène cible dans un organisme vivant ou dans des cellules cultivées. L'invention concerne également des protéines de fusion appropriées et une méthode de production desdites protéines de fusion.
CA002396149A 2000-01-07 2001-01-05 Transduction de recombinases pour ciblage genetique inductible Abandoned CA2396149A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP00100351A EP1118668A1 (fr) 2000-01-07 2000-01-07 Transduction d'une recombinase pour le ciblage inductible de gènes
EP00100351.6 2000-01-07
EP00124595.0 2000-11-10
EP00124595 2000-11-10
PCT/EP2001/000060 WO2001049832A2 (fr) 2000-01-07 2001-01-05 Transduction de recombinases pour ciblage genetique inductible

Publications (1)

Publication Number Publication Date
CA2396149A1 true CA2396149A1 (fr) 2001-07-12

Family

ID=26070411

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002396149A Abandoned CA2396149A1 (fr) 2000-01-07 2001-01-05 Transduction de recombinases pour ciblage genetique inductible

Country Status (6)

Country Link
EP (1) EP1244796A2 (fr)
JP (1) JP2003518947A (fr)
AU (1) AU3368301A (fr)
CA (1) CA2396149A1 (fr)
IL (1) IL150510A0 (fr)
WO (1) WO2001049832A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6773920B1 (en) 1999-03-31 2004-08-10 Invitrogen Corporation Delivery of functional protein sequences by translocating polypeptides
WO2003070931A2 (fr) * 2002-02-21 2003-08-28 Vision 7 Gmbh Techniques de recombinaison d'adn a des sites specifiques
AU2003210422A1 (en) * 2002-03-09 2003-09-22 Artemis Pharmaceuticals Gmbh Recombinase fusion protein with enhanced cellular uptake
EP1342781A1 (fr) * 2002-03-09 2003-09-10 ARTEMIS Pharmaceuticals GmbH Protéine de fusion de recombinase avec une assimilation cellulaire accrue
CN100410369C (zh) * 2006-06-22 2008-08-13 复旦大学 经tat和nls多肽修饰的φc31整合酶蛋白及其应用
DK2120987T3 (en) 2007-03-02 2014-02-24 Nono Inc Treatment of stroke and other diseases without inhibiting N-type calcium channels
US8110719B2 (en) * 2008-04-25 2012-02-07 New York Blood Center, Inc. ABI1 conditional knockout mouse
EP2527448A1 (fr) 2011-05-23 2012-11-28 Novozymes A/S Intégrations simultanées spécifiques au site de copies de plusieurs gènes dans des champignons filamenteux

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0903408A3 (fr) * 1992-08-21 2005-11-02 Biogen, Inc. Polypeptide de transport dérivé de la protéine tat
US6495526B2 (en) * 1996-01-23 2002-12-17 Gpc Biotech, Inc. Inhibitors of cell-cycle progression and uses related thereto
US6017735A (en) * 1997-01-23 2000-01-25 Marie Curie Cancer Care Materials and methods for intracellular transport and their uses
GB9718609D0 (en) * 1997-09-02 1997-11-05 Imp College Innovations Ltd Fusion protein
WO1999029721A1 (fr) * 1997-12-10 1999-06-17 Washington University Systeme anti-pathogene et procedes d'utilisation
JP2002505341A (ja) * 1998-03-06 2002-02-19 オックスフォード バイオメディカ（ユーケイ）リミテッド プロドラッグの活性化の増強
JP2002512808A (ja) * 1998-04-28 2002-05-08 ワシントン ユニバーシティー 融合タンパク質の形質導入法
GB9810423D0 (en) * 1998-05-15 1998-07-15 Cancer Res Campaign Tech Ionizing radiation or diathermy-switched gene therapy vectors and their use in antitumour therapy
EP1165819A2 (fr) * 1999-03-31 2002-01-02 Invitrogen Corporation Diffusion de sequences de proteines fonctionnelles par translocation de polypeptides
WO2000061617A2 (fr) * 1999-04-12 2000-10-19 Modex Therapeutiques, S.A. Cellules transitoirement immortalisees pour therapie genique

Also Published As

Publication number Publication date
IL150510A0 (en) 2003-02-12
JP2003518947A (ja) 2003-06-17
AU3368301A (en) 2001-07-16
WO2001049832A3 (fr) 2002-02-21
WO2001049832A2 (fr) 2001-07-12
EP1244796A2 (fr) 2002-10-02

Similar Documents

Publication Publication Date Title
AU2020255735B2 (en) Genetically modified immune cell, preparation method therefor, and application
KR102606929B1 (ko) 동족 항원과 t-세포 수용체 상호작용의 발견 및 특징규명을 위한 조작된 2-부분 세포 디바이스
KR101982360B1 (ko) 콤팩트 tale-뉴클레아제의 발생 방법 및 이의 용도
DK2718440T3 (en) NUCLEASE ACTIVITY PROTEIN, FUSION PROTEINS AND APPLICATIONS THEREOF
US20040003420A1 (en) Modified recombinase
KR101470472B1 (ko) 장기 지속형 약물 제형
CN114835821B (zh) 一种高效特异实现碱基颠换的编辑系统、方法及用途
KR102614328B1 (ko) T-세포 수용체 합성 및 tcr-제시 세포에 대한 안정적인 게놈 통합을 위한 2-부분 디바이스
KR20210151785A (ko) 비바이러스성 dna 벡터 및 fviii 치료제 발현을 위한 이의 용도
CN109069668A (zh) 用于眼病的基因疗法
KR101591887B1 (ko) 장기 지속형 약물 제형
WO2001049832A2 (fr) Transduction de recombinases pour ciblage genetique inductible
CN112203697A (zh) 编码氨基己糖苷酶alpha和beta亚基的双顺反子AAV载体及其用途
GB2443186A (en) Expression system for mediating alternative splicing
US12391948B2 (en) RNA-regulated fusion proteins and methods of their use
CA2502664A1 (fr) Silencage genique induit par sirna chez les animaux transgeniques
KR102027400B1 (ko) 정의된 항원에 대한 보호 체액성 면역 반응을 형성하는 재조합 효모를 이용한 예방 접종
WO2002020737A2 (fr) Ingenierie genomique par recombinases specifiques a un site adn et permeables a des cellules
CN113943749A (zh) 一种基于crispr基因编辑系统提高同源重组效率的方法
CN116323955A (zh) 通过crispr/cas介导的体内末端解析拯救重组腺病毒
EP1395612A2 (fr) Recombinase modifiee
CN112831524B (zh) 人工改造的重组腺病毒载体、由其包装的病毒及其应用
CN111991550B (zh) Hip-55在制备用于诊断和防治心肌缺血再灌注损伤产品中的应用
CA2620294A1 (fr) Therapie genique oculaire utilisant la transfection mediee par avalanche
US20030078406A1 (en) Methods and compositions for DRM, a secreted protein with cell growth inhibiting activity

Legal Events

Date Code Title Description
FZDE Discontinued